Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors

Cancer Genetics and Cytogenetics

Volumn 112, Issue 2, 1999, Pages 105-118

  Tworek, Henry ^a   Peng, Ruoqi ^a   Fetzer, Sean ^a   Werness, Bruce A ^a   Piver, M Steven ^a   Allen, Howard J ^a   Dicioccio, Richard A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

CONTROLLED STUDY; DNA SEQUENCE; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; ONCOGENE; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

EID: 0033035921     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(98)00267-2     Document Type: Article

References (106)

1. American Cancer Society (1998): Cancer Facts and Figures - 1998.
2. Weinberg R.A. The genetic origins of cancer. Cancer. 61:1988;1963-1968.
3. Sager R. Tumor suppressor genes. Science. 246:1989;1406-1412.
4. Bishop J.M. Molecular themes in carcinogenesis. Cell. 64:1991;235-248.
5. Hunter T. Cooperation between oncogenes. Cell. 64:1991;249-270.
6. Marshall C.J. Tumor suppressor genes. Cell. 64:1991;313-326.
7. Levine A. The tumor suppressor genes. Ann Rev Biochem. 62:1993;623-651.
8. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 9:1993;138-141.
9. Katso R.M.T., Manek S., O'Byrne K., Playford M.P., LeMeuth V., Ganesan T.S. Molecular approaches to the diagnosis and management of ovarian cancer. Cancer Metastasis Rev. 16:1997;81-107.
10. Newman B., Millikan R.C., King M.C. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev. 19:1997;69-79.
11. Chuaqui R.F., Zhuang Z., Merino M.J. Molecular genetic events in the development and progression of ovarian cancer in humans. Mol Med Today. 3:1997;207-213.
12. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B., King M.C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 250:1990;1684-1689.
13. Miki Y., Swenson J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugen-Strano A., Katcher H., Yakumo K., Gholami Z., Shaffer D., Stone S., Bayer S., Wray C., Bogden R., Dayananth P., Ward J., Tonin P., Narod S., Bristow P.K., Norris F.H., Helvering L., Morrison P., Rosteck P., Lai M., Barrett J.C., Lewis C., Neuhausen S., Cannon-Albright L., Goldgar D., Wiseman R., Kamb A., Skolnick M.H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
14. Monteiro A.N.A., August A., Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA. 93:1996;13595-13599.
15. Chapman M.S., Verma I.M. Transcriptional activation by BRCA1. Nature. 382:1996;678-679.
16. Skully R., Anderson S.E., Chao D.M., Wei W., Ye L., Young R.A., Livingston D.M., Parvin J.D. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA. 94:1997;5605-5610.
17. Skully R., Chen J., Plug A., Xiao Y., Weaver D., Feuteun J., Ashley T., Livingston D.M. Association of BRCA1 with RAD51 in mitotic and meiotic cells. Cell. 88:1997;265-275.
18. Ford D., Easton D.F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution of breast and ovarian cancer incidence. Am J Hum Genet. 57:1995;1457-1462.
19. Takahashi H., Behbakht K., McGovern P.E., Chiu H.C., Couch F.J., Weber B.L., Friedman L.S., King M.C., Furusato M., LiVolsi V.A., Menzin A.W., Liu P.C., Benjamin I., Morgan M.A., King S.A., Rebune B.A., Cardonick A., MiKuta J., Rubin S.C., Boyd J. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 55:1995;2998-3002.
20. Matsushima M., Kobayashi K., Emi M., Saito H., Saito J., Suzumori K., Nakamura Y. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients. four germline mutations, but no evidence of somatic mutation Hum Mol Genet. 4:1995;1953-1956.
21. Whittemore A.S., Gong G., Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer. results from three U.S. population-based case-controlled studies of ovarian cancer Am J Hum Genet. 60:1997;496-504.
22. Stratton J.F., Gayther S.A., Russell P., Deardon J., Gore M., Blake P., Easton D., Ponder B.A.J. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 336:1997;1125-1130.
23. Smith S.A., Easton D.F., Evans D.G.R., Ponder B.A.J. Allele loss in the region 17q12-21 in familial breast and ovarian cancer involving the wild-type chromosome. Nature Genet. 2:1992;128-131.
24. Kelsell D.P., Black D.M., Bishop D.T., Spurr N.K. Genetic analysis of the BRCA1 region in a large breast/ovarian family. refinement of the minimal region containing BRCA1 Hum Mol Genet. 2:1993;1823-1826.
25. Futreal A.P., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., Bennett L.M., Haugen-Strano A., Swensen J., Miki Y., Eddington K., McClure M., Frye C., Weaver-Feldhaus J., Ding W., Gholami Z., Soderkvist P., Terry L., Jhanwar S., Berchuk A., Iglehart J.D., Marks J., Ballinger D.G., Barrett J.C., Skolnick M.H., Kamb A., Wiseman R. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 266:1994;120-122.
26. Castilla L.H., Couch F.J., Erdos M.R., Hoskins K.F., Calzone K., Garber J.E., Boyd J., Lubin M.B., Deshano M.L., Brody L.C., Collins F.S., Weber B.L. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nature Genet. 8:1994;387-391.
27. Friedman L.S., Ostermeyer E.A., Lynch E.D., Szabo C.I., Anderson L.A., Dowd P., Ming K., Rowell S.E., Boyd J., King M.C. The search for BRCA1. Cancer Res. 54:1994;6374-6382.
28. Neuhausen S.L., Marshall C.J. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 54:1994;6069-6072.
29. Takano M., Aida H., Tsuneki I., Takakawa K., Hasegawa I., Tanaka H., Saito M., Tsuji S., Sonoda T., Hatae M., Chen J.T., Takahashi K., Hasegawa K., Toyoda N., Saito N., Yakushiji M., Araki T., Tanaka K. Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan. Jpn J Cancer Res. 88:1997;407-413.
30. Shelling A.N., Cooke I.E., Ganesan T.S. The genetic analysis of ovarian cancer. Br J Cancer. 72:1995;521-527.
31. Hosking L., Trowsdale J., Nicolai H., Soloman E., Foulkes W., Stamp G., Signer E., Jefferys A. A somatic BRCA1 mutation in an ovarian tumor. Nature Genet. 9:1995;343-344.
32. Merajver S.D., Phan T.M., Caduff R.F., Chen M., Poy E.L., Cooney K.A., Weber B.L., Collins F.S., Johnston C., Frank T.S. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet. 9:1995;439-443.
33. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene. clues to cancer etiology and molecular pathogenesis Cancer Res. 54:1994;4855-4878.
34. Furihata M., Sonobe H., Ohtsuki Y. The aberrant p53 protein. Int J Oncol. 6:1995;1209-1226.
35. Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta. 1287:1996;77-102.
36. Soussi T. The p53 tumor suppressor gene. a model for molecular epidemiology of human cancer Mol Med Today. 2:1996;32-37.
37. Kiaris H., Spandidos D.A. Mutations in ras genes in human tumours (review). Int J Oncol. 7:1995;413-421.
38. Enemoto T., Weghorst C.M., Inoue M., Tanizawa O., Rice J.M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol. 139:1991;777-785.
39. Mok S.C.H., Bell D.A., Knapp R.C., Fishbaugh P.M., Welch W.R., Muto M.G., Berkowitz R.S., Tsao S.W. Mutation of K-ras proto-oncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53:1993;1489-1492.
40. Teneriello M.G., Ebina M., Linnoila R.I., Henry M., Nash J.D., Park R.C., Birrer M.J. p53 and Ki ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53:1993;3103-3108.
41. Fujita M., Enomoto T., Inoue M., Tanizawa O., Osaki M., Rice J.M., Nomura T. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res. 85:1994;1247-1256.
42. Ichikawa Y., Nishida M., Suzuki H., Yoshida S., Tsunoda H., Kubo T., Uchida K., Miwa M. Mutation of K-ras proto-oncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 54:1994;33-35.
43. Chenevix-Trench G., Kerr J., Hurst T., Shih Y.C., Purdie D., Bergman L., Friedlunder M., Sanderson B., Zournazi A., Coombs T., Leary J.A., Crawford E., Shelling A.N., Cooke I., Gamesan T.S., Searle J., Choi C., Barrett J.C., Khoo S.K., Ward B. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms. clinicopathological correlations Genes Chromosom Cancer. 18:1997;75-83.
44. Cautrecases M., Villanueva A., Matias-Guiu X., Prat J. K-ras mutations in mucinous ovarian tumors. Cancer. 79:1997;1581-1586.
45. Caduff R.F., Svoboda-Newman S., Bartos R., Ferguson A.W., Frank T.S. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am J Surg Pathol. 22:1998;319-326.
46. Brugarolas J., Jacks T. Double indemnity. p53 BRCA and cancer Nat Med. 3:1997;721-722.
47. Bertwistle D., Ashworth A. Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev. 8:1998;14-20.
48. WAF1-CIP1. Nature. 389:1997;187-190.
49. 5-6 early embryonic lethality by p53 or p21 null mutation. Nature Genet. 16:1997;298-302.
50. Ludwig T., Chapman D.L., Papaioannou V.E., Efstratiadis A. Target mutations of breast cancer susceptibility gene homologs in mice. lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and BRCA2/p53 nullizygous embryos Genes Dev. 11:1997;1226-1241.
51. Ouchi T., Monteiro A.N.A., August A., Aaronson S.A., Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA. 95:1998;2302-2306.
52. Zhang H., Somasundarum K., Peng Y., Tion H., Zhang H., Bi D., Weber B.L., El-Deiry W. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 16:1998;1713-1721.
53. DiCioccio R.A., Siniscalco M. Human m-RNA transcripts in man-mouse somatic cell hybrids. II. Thermal denaturation studies and cot analysis. Somat Cell Mol Genet. 1:1975;263-277.
54. DiCioccio R.A., Werness B.A., Peng R., Allen H.J., Piver M.S. Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet. 103:1998;1-10.
55. Wong C., DiCioccio R.A., Allen H.J., Werness B.A., Piver M.S. Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation. Cancer Genet Cytogenet. 107:1998;21-27.
56. Gayther S.A., Warren W., Mazoyer S., Russell P.A., Harrington P.A., Chiano M., Seal S., Hamoudi R., van Rensburg E.J., Dunning A.M., Love R., Evans G., Easton D., Clayton D., Strutton M.R., Ponder B.A.J. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet. 11:1995;428-433.
57. Suzuki Y., Orita M., Shiraishi M., Hayashi K., Sekiya T. Detection of ras gene mutations in human lung cancers by single strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene. 5:1990;1037-1043.
58. DiCioccio R.A., Piver M.S. A polymorphism in intron 2 of the TP53 gene. Clin Genet. 50:1996;108-109.
59. Orita M., Suzuki Y., Sekiya T., Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5:1989;874-879.
60. DiCioccio R.A., Brown K.S. Biosynthesis, processing, and extracellular release of (α-L-fucosidase in lymphoid cell lines of different genetic origins. Biochem Genet. 26:1988;401-419.
61. Brody LC, The Breast Cancer Information Core Steering Committee (1998): Breast cancer information core: an online database. (website) http://www/nhgri.nih.gov/.Intramural_ Research/Lab_transfer/Bic/.
62. Smith T.M., Lee M.K., Szabo C.I., Jerome N., McEuen M., Taylor M., Hood L., King M.C. Complete genomic sequence and analysis of human DNA containing the gene BRCA1. Genome Res. 6:1996;1029-1049.
63. Ad Hoc Committee on Mutation Nomenclature Update on nomenclature for human gene mutations. Hum Mutat. 8:1996;197-202.
64. Xu C.F., Brown M.A., Chambers J.A., Griffiths B., Solomon E. Distinct transcription start sites generate two forms of BRCA1 mRNA. Hum Mol Genet. 4:1995;2259-2264.
65. Fetzer S., Tworek H.A., Piver M.S., DiCioccio R.A. An alternative splice site junction in exon 1a of the BRCA1 gene. Cancer Genet Cytogenet. 105:1998;90-92.
66. Couch F.J., Weber B.L., the Breast Cancer Information Core Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Hum Mutat. 8:1996;8-18.
67. Durocher F., Tonin P., Shattuck-Eidens D., Skolnick M., Narod S.A., Simard J. Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. J Med Genet. 33:1996;814-819.
68. Hamann U., Brauch H., Garvin A.M., Basert G., Scott R.J. German family study on hereditary breast and/or ovarian cancer. germline mutation analysis of the BRCA1 gene Genes Chromosom Cancer. 18:1997;126-132.
69. Friedman L.S., Ostermeyer E.A., Szabo C.I., Dowd P., Lynch E.D., Rowell S.E., King M.C. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genet. 8:1994;399-404.
70. Durocher F., Shattuck-Eidens D., McClure M., Labrie F., Skolnick M.H., Goldgar D.E., Simard J. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet. 5:1996;835-842.
71. Dunning A.M., Chiano M., Smith N.R., Dearden J., Gore M., Oakes S., Wilson C., Stratton M., Peto J., Easton D., Clayton D., Ponder B.A. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Molec Genet. 6:1997;285-289.
72. Greenman J., Mohammed S., Ellis D., Watts S., Scott G., Izatt L., Barnes D., Solomon E., Hodgson S., Matthew C. Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer. Genes Chromosom Cancer. 21:1998;244-249.
73. Peyrat J.P., Vennin P., Hornez L., Fournier J., Adenis C., Bonneterre J. Germline BRCA1 mutations in patients from 84 families with breast and/or ovarian cancers in northern France. Eur J Cancer Prev. 7:1998;S7-S12.
74. Jandrig B., Grade K., Seitz S., Waindzoch B., Muller M., Bender E., Nothnagel A., Rohde K., Schiag P.M., Kath R., Hoffken K., Scherneck S. BRCA1 mutations in German breast-cancer families. Int J Cancer. 68:1996;188-192.
75. Oriola J., Titos E., Leivas A., Navarro M.A., Rivera-Fillat F. Two new polymorphisms in the BRCA1 gene. Clin Genet. 5:1997;361-362.
76. 4-terminal BRCA1 RING finger domain. J Biol Chem. 14:1998;7795-7799.
77. Wu L.C., Wang Z.W., Tsan J.T., Spillman M.A., Phung A., Yang M.C.W., Hwang L.Y., Bowcock A.M., Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nature Genet. 14:1996;430-440.
78. Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A., Ishov A.M., Tommerup N., Vissing H., Sekido Y., Minn J., Borodovsky A., Schultz D.C., Wilkinson K.D., Maul G.G., Barlev N., Berger S.L., Prendergast G.C., Rausher F.J. III BAP1. a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression Oncogene. 16:1998;1097-1112.
79. Crook T., Crossland S., Crompton M.R., Osin P., Gusterson B.A. p53 mutations in BRCA1-associated familial breast cancer. Lancet. 350:1997;638-639.
80. Glebov O.K., McKensie K.E., White C.A., Sukumar S. Frequent p53 gene mutations and novel alleles in familial breast cancer cases. Cancer Res. 54:1994;3703-3709.
81. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M.D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T.R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B.A.J., Gayther S.A., Birch J.M., Lindblom A., Stoppa-Lyonnet D., Bignon Y., Borg A., Hamann U., Haites N., Scott R.J., Maugard C.M., Vasen H., Seitz S., Cannon-Albright L.A., Schofield A., Zelada-Hedman M., the Breast Cancer Linkage Consortium Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 62:1998;676-689.
82. Sobol H., Stoppa-Lyonnett D., Bressac-DePuillerets B., Peyrat J.P., Guinebretiere J.M., Jacquemier J., Eisinger F., Birnbaum D. BRCA1-p53 relationship in hereditary breast cancer. Int J Oncol. 10:1997;349-353.
83. Thor A.D., Moore D.H., Edgerton S.M., Kawasaki E.S., Reihsaus E., Lynch H.T., Marcus J.N., Schwartz L., Chen L.C., Mayall B.H., Smith H.S. Accumulation of p53 tumor suppressor gene protein. an independent marker of prognosis in breast cancers J Natl Cancer Inst. 84:1992;845-855.
84. Wynford-Thomas D. p53 in tumor pathology. can we trust immunohistochemistry? J Pathol. 166:1992;329-330.
85. Hall P.A., Lane D.P. p53 in tumor pathology. can we trust immunohistochemistry? Revisited J Pathol. 172:1994;1-4.
86. Sjogren S., Inganas M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer. prognostic value of complementary DNA sequencing versus immunohistochemistry J Natl Cancer Inst. 88:1996;173-182.
87. Mizuuchi H., Mori Y., Sato K., Kamiya H., Okamura N., Nasim S., Garrett C., Kudo R. High incidence of point mutation in K-ras codon 12 in carcinoma of the fallopian tube. Cancer. 76:1995;86-90.
88. Moll U.M., Riou G., Levine A.J. Two distinct mechanisms alter p53 in breast cancer. mutation and nuclear exclusions Proc Natl Acad Sci USA. 89:1992;7262-7266.
89. Momand J., Zembetti G.P., Olson D.C., George D., Levine A.J. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
90. Chen Y., Chen C.F., Riley D.J., Allred C., Chen P.L., Von Hoff D., Osborne C.K., Lee W.H. Aberrant subcellular localization of BRCA1 in breast cancer. Science. 270:1995;789-791.
91. Thompson M.E., Jensen R.A., Obermiller P.S., Page D.L., Holt J.L. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet. 9:1995;444-450.
92. Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57:1997;3347-3350.
93. Mancini D.M., Rodenhiser D.I., Ainsworth P.J., O'Malley F.P., Singh S.M., Xing W., Archer T.K. CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene. 16:1998;1161-1169.
94. Schorge J.O., Muto M.G., Welch W.R., Bandera C.A., Rubin S.C., Bell D.A., Berkowitz R.S., Mok S.C. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst. 90:1998;841-845.
95. Knudson A.G. Jr. Mutation and cancer. a statistical study of retinoblastoma Proc Natl Acad Sci USA. 68:1971;820-823.
96. Haber D.A., Housman D.E. Rate limiting steps. the genetics of pediatric cancers Cell. 64:1991;5-8.
97. Amos C.I., Shaw G.L., Tucker M.A., Hartge P. Age at onset for familial epithelial ovarian cancer. JAMA. 268:1992;1896-1899.
98. Piver M.S., Goldberg J.M., Tsukada Y., Mettlin C.J., Jishi M.F., Natarajan N. Characteristics of familial ovarian cancer. a report of the first 1000 families in the Gilda Radner Familial Ovarian Cancer Registry Eur J Gynaecol Oncol. 17:1996;169-176.
99. Ries LAG, Hankey BF, Miller BA, Hartman AM, Edwards BK (1992): Cancer statistics review: 1973-1989. National Cancer Institute. NIH Publication Number 92-2789.
100. Claus E.B., Schildkraut J.M., Thompson W.D., Risch N.J. The genetic attributable risk of breast and ovarian cancer. Cancer. 7:1996;2318-2324.
101. Schildkraut J.M., Thompson W.D. Familial ovarian cancer. a population-based case-control study Am J Epidemiol. 128:1988;456-466.
102. Schildkraut J.M., Thompson W.D. Relationship of epithelial ovarian cancer to other malignancies within families. Genet Epidemiol. 5:1988;355-357.
103. Amos C.I., Struewing J.P. Genetic epidemiology of epithelial ovarian cancer. Cancer. 7:1993;566-572.
104. Houlston R.S., Bourne T.H., Collins W.P., Whitehead M.I., Campbell S., Slack J. Risk of ovarian cancer and genetic relationship to other cancers in families. Hum Hered. 43:1993;111-115.
105. Hartge P., Whittemore A.S., Itnyre J., McGowan L., Cramer D., the Collaborative Ovarian Cancer Group Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol. 84:1994;760-764.
106. Auranen A., Pukkala E., Makinen J., Sankila R., Grenman S., Salmi T. Cancer incidence in the first-degree relatives of ovarian cancer patients. Br J Cancer. 74:1996;280-284.